Unum Therapeutics Inc. (UMRX) Prices 5.77M Share IPO at $12/Sh

Unum Therapeutics Inc. (NASDAQ: UMRX) (“Unum Therapeutics”), a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer, today announced the pricing of its initial public offering of 5,770,000 shares of common stock at a public offering price of $12 per share. In addition, Unum Therapeutics has granted the underwriters a 30-day option to purchase up to 865,500 additional shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Unum Therapeutics’ common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "UMRX" on March 29, 2018. The offering is expected to close on April 3, 2018, subject to customary closing conditions.

Morgan Stanley and Cowen are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey and Wedbush PacGrow are acting as lead managers.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Eightco Holdings reports $380M in total treasury holdings
• Rent the Runway agrees to $9M settlement in IPO securities lawsuit